Charles Theuer, President and CEO at Tracon Pharmaceuticals, Inc. (TCON), bought 1,200 shares at $2.45 ($3K) on 2022-03-21, disclosed to the SEC on 2022-03-23.
Open-market purchase of $3k TCON by President and CEO. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| TCON | BUY | 2023-01-19 | $11K | — | Filing → |
| TCON | BUY | 2022-12-15 | $30K | — | Filing → |
| TCON | BUY | 2022-11-22 | $20K | — | Filing → |